CGONHealthcare · BiotechnologyThe 15 Wall Street analysts covering CG Oncology, Inc. hold a median 12-month price target of $90 — +24.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores CG Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (91): The shares have been drifting up relative to others.
Quality (10): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CGON, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +24.4% from it.
Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | Piper Sandler | Maintains | Overweight | $82 → $85 |
| 7 Aug 2026 | RBC Capital | Maintains | Outperform | $81 → $79 |
| 7 Aug 2026 | Truist Securities | Maintains | Buy | $82 → $85 |
| 19 May 2026 | Wolfe Research | Initiates | Peer Perform | — |
| 19 May 2026 | Wolfe Research | Initiates | Peer Perform | — |
| 18 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $100 |
| 18 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2026 | Truist Securities | Reiterates | Buy | $77 → $82 |
| 14 May 2026 | Truist Securities | Reiterates | Buy | — |
| 11 May 2026 | JP Morgan | Maintains | Overweight | — |
| 11 May 2026 | RBC Capital | Maintains | Outperform | — |
| 11 May 2026 | Truist Securities | Reiterates | Buy | — |
| 11 May 2026 | Wedbush | Maintains | Outperform | — |
| 27 Apr 2026 | RBC Capital | Maintains | Outperform | — |
| 17 Apr 2026 | JP Morgan | Maintains | Overweight | — |
| 7 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 27 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Feb 2026 | Truist Securities | Maintains | Buy | — |
| 21 Jan 2026 | RBC Capital | Maintains | Outperform | — |
| 16 Jan 2026 | Piper Sandler | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CGON appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, CG Oncology, Inc. returned +118.1% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 98% of US stocks
Cheaper than 1% of US stocks
Cheaper than 16% of US stocks
Cheaper than 90% of US stocks
Higher than 44% of US stocks
Higher than 98% of US stocks
Higher than 1% of US stocks
Higher than 2% of US stocks
Higher than 17% of US stocks
Higher than 28% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CG Oncology, Inc. has a market value of $6.4B and an enterprise value of $5.4B.
Revenue in the twelve months to 30 June 2026: $6.2M. The latest quarter grew 6.8% year on year.
Net income over the same four quarters: −$224.4M, a −3602.7% net margin.
Free cash flow in the twelve months to 30 June 2026: −$179.3M.
Trailing P/E: −34.8×; forward P/E: −24.0× — the forward figure prices analyst consensus estimates, not reported earnings.
CG Oncology, Inc. employs 142 people — $44K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own CG Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Schaeffers Research reports that YPF, CGON, and IE are seeing unusually heavy call volume from options traders today. The item highlights CGON among stocks drawing notable options activity.
Why it matters — Heavy call volume in CGON indicates elevated trader interest and options activity in the stock, which a CGON watcher would want to be aware of.
Schaeffers Research published a list of 15 stocks with short squeeze potential, noting that bond yields have put markets on edge and that most investors are not currently focused on short squeezes. The piece suggests such stocks could be of interest to contrarian traders.
Why it matters — CGON was featured among stocks with short squeeze potential, which may be of interest to watchers tracking positioning and contrarian trading dynamics.
CG Oncology announced that CEO Arthur Kuan will participate in fireside chat presentations at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in New York City in September 2026. The company disclosed details of the upcoming investor conference events.
Why it matters — CG Oncology watchers would care because the presentations offer an opportunity for investors to hear directly from the CEO at two major healthcare conferences.
CG Oncology is advancing cretositimogene grenadenorepvec (cret) for NMIBC, reporting strong efficacy and best-in-class safety versus competitors, including a 75% anytime CR, 46% 12-month CR, and 42% 24-month CR in BOND-003 Cohort C with no Grade 3+ adverse events. The rolling BLA for cret in HR BCG-unresponsive NMIBC is expected to complete in 4Q26, with multiple trial readouts in 2H26 and 2027.
Why it matters — CGON watchers would care because the cret efficacy and safety data, along with the upcoming BLA completion and trial readouts, mark key regulatory and clinical milestones for the company's lead program.
CG Oncology, Inc. reported a quarterly loss of $0.9 per share for the quarter, which was wider than the Zacks Consensus Estimate of a $0.7 loss and compared with a loss of $0.54 per share a year earlier. The company missed revenue estimates.
Why it matters — CGON watchers would care because the company's quarterly results came in below analyst expectations on both earnings and revenue.
The 15 Wall Street analysts covering CG Oncology, Inc. have a median 12-month price target of $90, with estimates ranging from $79 to $108. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 15 analysts covering CG Oncology, Inc., 14 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CG Oncology, Inc. 17 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, CG Oncology, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (91 of 100).
No one can know that. What the data says: the median 12-month target from 15 analysts implies +24.4% from the last close, and Ticker Nerd's factor model ranks CG Oncology, Inc. 17 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering CG Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CGON are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $79 to $108 over the next 12 months.
CG Oncology, Inc. returned +118.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
CG Oncology Inc. is a clinical biopharmaceutical company focused on bladder cancer, with an emphasis on bladder-sparing therapies for patients with non-muscle invasive disease.
The most recent item we track (Schaeffers Research, 11 Sept 2026): "3 Stocks Call Traders Are Targeting Today". Schaeffers Research reports that YPF, CGON, and IE are seeing unusually heavy call volume from options traders today. The item highlights CGON among stocks drawing notable options activity.
CG Oncology Inc. is a clinical biopharmaceutical company focused on bladder cancer, with an emphasis on bladder-sparing therapies for patients with non-muscle invasive disease. The company’s lead product candidate, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic immunotherapy designed to act directly within the bladder and engage the immune system against tumors. CG Oncology is developing this therapy across multiple current clinical programs for high-risk and intermediate-risk bladder cancer settings, including combination studies with other oncology treatments. The company’s work centers on addressing unmet needs in urologic oncology through localized treatment approaches that aim to preserve the bladder while targeting disease at the source.
CEO Mr. Arthur Kuan · 142 employees · United States · https://cgoncology.com
